Azitra, Inc. (AZTR)
AZTRAMEXBiotechnology: Pharmaceutical Preparations
$0.6200
-0.0240 (-3.73%) today
Closed, Nov 10, 4:00 PM ET
- Market cap
- $3.64m
- P/E
- –
- EPS, last 4 quarters
- –
- Dividend yield
- –
- Day range
- –
- 52-week range
- $0.5180 to $4.30
- Average volume
- –
- Previous close
- $0.6440
Earnings
next estimate $-0.2500Next report
Mar 2026
–
Jun 2026
+19.1%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$2.77m | -$2.23m | -$3.93m | -$3.42m |
| Net income | -$2.77m | -$2.23m | -$3.93m | -$3.35m |
News
8 latest- Azitra Consensus Price Target Increased by 900% to $6.83Fintel · Nov 2, 2026
- Azitra, Inc. Expands Eligibility for ATR-04 Phase 1/2 Clinical TrialFintel · Oct 29, 2026
- Azitra, Inc. Pauses ATM Program and Announces Ex Vivo Results for ATR-COSFFintel · Oct 26, 2026
- Azitra, Inc. Announces 1-for-10 Reverse Stock SplitFintel · Oct 22, 2026
- Azitra To Implement 1-for-10 Reverse Stock Split RTTNews · Oct 16, 2026
- Azitra Consensus Price Target Decreased by 13.55% to $0.68Fintel · Oct 2, 2026
- Top Biotech Gainers: TNON Files S-1, NVCT Inks License Deal, FTH On Watch, RGNX To Resubmit BLA RTTNews · Jun 22, 2026
- Azitra (AZTR) Price Target Decreased by 50.00% to 1.38Fintel · Mar 27, 2026
The company
Azitra, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology and novel products across therapeutics, cosmeceuticals and biotechnology applications. The Company's portfolio is highlighted by ATR-COSF, a recombinant protein technology designed for cosmetic and skincare applications, and ATR-04, an investigational live biotherapeutic for skin rashes associated with cancer and neurofibromatosis treatments. Azitra has received Fast Track designation from the FDA for cancer treatment-associated rash, which impacts up to 300,000 people in the U.S. Azitra is also advancing additional recombinant protein initiatives designed to support biotechnology research and manufacturing applications. Azitra's technology platforms combine engineered proteins, topical live biotherapeutics, artificial intelligence, and a proprietary microbial library to develop differentiated products for consumer, research and healthcare markets.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- AMEX
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.